Full Text of PDF (531k)
Article in Japanese
Abstract
Case Report
A case of single-dose pembrolizumab-induced pituitary dysfunction six months subsequent to thyroid dysfunction
Midori Hashimoto Haruka Takahashi Tatsuru Ishikawa Kaoru Nishiyama
Department of Pulmonary Diseases, NTT Medical Center Sapporo
ABSTRACT
A 66-year-old man who had undergone chemoradiotherapy for non-small lung cancer was treated with levothyroxine sodium because he developed thyrotoxicosis and thyroid dysfunction two weeks after receiving one dose of pembrolizumab. He developed hypophysitis six months later. A recent review pointed out that the median time to onset of pituitary damage secondary to ongoing treatment with PD-1 antibody is five months. However, the present case involved hypophysitis six months after a single administration of pembrolizumab, therefore the potential of immune-related adverse events (irAEs) even after the expected period should be kept in mind.
KEYWORDS
Immune checkpoint inhibitor (ICI) Lung cancer Immune-related adverse event (irAE) Pituitary dysfunction Hypothyroidism
Received 4 Mar 2019 ／ Accepted 15 May 2019
AJRS, 8(5): 307-311, 2019
Copyright © The Japanese Respiratory Society All Rights Reserved.